Patents Assigned to Wyeth
  • Publication number: 20030114444
    Abstract: This invention provides a method of treating pain in a mammal that includes administering to a mammal in need of such treatment a pain treating effective amount of a compound of the formula (I): 1
    Type: Application
    Filed: October 9, 2002
    Publication date: June 19, 2003
    Applicant: Wyeth
    Inventors: Michael Richard Brandt, Margaret Maria Zaleska, John Allen Moyer
  • Publication number: 20030109523
    Abstract: This invention provides novel bicyclic compounds of Formula (I): 1
    Type: Application
    Filed: June 6, 2002
    Publication date: June 12, 2003
    Applicant: Wyeth
    Inventors: Arie Zask, Diane B. Hauze, Kenneth L. Kees, Richard D. Coghlan, John Yardley
  • Publication number: 20030109513
    Abstract: This invention provides 3&bgr;-hydroxy-5,7,9-estratriene-17-one and a pharmaceutically acceptable salt of its 3-sulfate ester, which is useful as an estrogen.
    Type: Application
    Filed: January 21, 2003
    Publication date: June 12, 2003
    Applicant: Wyeth
    Inventors: Syed M. Shah, Panolil Raveendranath, Michael Z. Kagan
  • Publication number: 20030109585
    Abstract: This invention relates to a highly thermally stable novel anhydrous crystalline polymorphic form of venlafaxine hydrochloride, methods for the preparation thereof, and its use.
    Type: Application
    Filed: December 3, 2002
    Publication date: June 12, 2003
    Applicant: Wyeth
    Inventors: Kadum Abdul Nabi Ali, Jun Han, Yong Jai Lee
  • Publication number: 20030108549
    Abstract: Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.
    Type: Application
    Filed: October 4, 2002
    Publication date: June 12, 2003
    Applicant: Wyeth
    Inventors: Laura Carter, Beatriz Carreno, Leslie D. Lowe, Matthew J. Whitters, Kyri Dunussi, Mary Collins, Margery Ma, Deborah A. Young, JoAnn S. Witek, Glenn Larsen, Marion T. Kasaian, Debra D. Donaldson, Michelle Unger
  • Publication number: 20030109750
    Abstract: A process for the preparation of 2-[alkyl(aryl)]sulfonylbenzene sulfonyl chlorides of the following formula is provided: 1
    Type: Application
    Filed: October 31, 2002
    Publication date: June 12, 2003
    Applicant: Wyeth
    Inventors: Jennifer P. Varriano, Lalitha Krishnan, Bogdan K. Wilk
  • Publication number: 20030109562
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: January 10, 2003
    Publication date: June 12, 2003
    Applicant: Wyeth
    Inventors: Megan Tran, Gary P. Stack
  • Publication number: 20030105342
    Abstract: A process for the stereoselective synthesis of 2-hydroxymethyl-chromans of formula (II) is provided 1
    Type: Application
    Filed: October 4, 2002
    Publication date: June 5, 2003
    Applicant: Wyeth
    Inventors: Jonathan L. Gross, Gary P. Stack
  • Publication number: 20030105358
    Abstract: The present invention provides an efficient method of making O-desmethyl-venlafaxine.
    Type: Application
    Filed: November 26, 2002
    Publication date: June 5, 2003
    Applicant: Wyeth
    Inventor: Beat Theodor Weber
  • Publication number: 20030104498
    Abstract: A process to excystate protozoal sporocysts involves treatment of an infected tissue sample with a sodium hypochlorite solution to stimulate excystation of the sporocysts from the tissue. Thereafter, removal of the sodium hypochlorite solution and treatment of the sample with a cell culture media as the excystation fluid eliminates incubation and subsequent washing steps using expensive reagents. The excystation fluid contains substantially no chelating agents, proteins, enzymes or bile acids.
    Type: Application
    Filed: October 15, 2002
    Publication date: June 5, 2003
    Applicant: Wyeth
    Inventors: Neil J. Jennings, Kirsten I. Dinka
  • Patent number: 6573283
    Abstract: Compounds of the formula: are useful for the treatment of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse and related illnesses.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: June 3, 2003
    Assignee: Wyeth
    Inventor: Gary P. Stack
  • Publication number: 20030100579
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: October 4, 2002
    Publication date: May 29, 2003
    Applicant: Wyeth
    Inventors: Jonathan Laird Gross, Richard Eric Mewshaw, Gary Paul Stack
  • Publication number: 20030100577
    Abstract: This invention provides non-immunosuppressive rapamycin dialdehydes, which are useful as neurotrophic agents, in the treatment of solid tumors, and vascular disease.
    Type: Application
    Filed: August 22, 2002
    Publication date: May 29, 2003
    Applicant: Wyeth
    Inventors: Tianmin Zhu, Mahdi B. Fawzi
  • Publication number: 20030100774
    Abstract: This invention provides a process for the stereospecific preparation of 2-yl-chroman and -chromene derivatives of the formula: 1
    Type: Application
    Filed: October 4, 2002
    Publication date: May 29, 2003
    Applicant: Wyeth
    Inventor: Jonathan L. Gross
  • Patent number: 6569873
    Abstract: This invention provides compounds of Formula I having the structure wherein, A, X, Y, Z, W, R1, R2, R3, R4, R5, and R6 are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: May 27, 2003
    Assignee: Wyeth
    Inventors: Michael Sotirios Malamas, Elwood Eugene Largis, Iwan Gunawan, Zenan Li
  • Publication number: 20030096356
    Abstract: Novel proteins which contain a structural module conserved in the G protein coupled receptor superfamily, polynucleotides which encode these proteins, and methods for producing these proteins are provided. Diagnostic, therapeutic, and screening methods employing the polynucleotides and polypeptides of the present invention are also provided.
    Type: Application
    Filed: July 18, 2002
    Publication date: May 22, 2003
    Applicant: Wyeth
    Inventors: Bradley A. Ozenberger, Eileen M. Kajkowski, Ching-Hsiung Frederick Lo, Heidi Sofia
  • Publication number: 20030096822
    Abstract: A homogenous, clear, veterinary gel composition which has a broad spectrum of efficacy against endoparasites over a prolonged period of time and which allows for higher concentrations of a mixture of parasiticidal agents in a single application. This composition is useful for treating and controlling endoparasiticidal infection and infestation in a homeothermic animal.
    Type: Application
    Filed: July 24, 2002
    Publication date: May 22, 2003
    Applicant: Wyeth
    Inventors: Shobhan S. Sabnis, Jon Hayes, Jack A. Zupan
  • Patent number: 6566375
    Abstract: Compounds of this invention increase plasma levels of high density lipoprotein or HDL, the “good” cholesterol and as such may be useful for treating diseases such as atherosclerosis.
    Type: Grant
    Filed: April 26, 2001
    Date of Patent: May 20, 2003
    Assignee: Wyeth
    Inventor: Thomas J. Commons
  • Patent number: 6566358
    Abstract: This invention provides compounds of Formula (I): wherein R1 and R2 may be single substituents or fused to form spirocyclic or hetero-spirocyclic rings; R3 is H, OH, NH2, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C6 alkenyl, substituted C1 to C6 alkenyl, alkynyl, or substituted alkynyl, CORC; RC is H, C1 to C3 alkyl, substituted C1 to C3 alkyl, aryl, substituted aryl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 aminoalkyl, or substituted C1 to C3 aminoalkyl; R4 is H, halogen, CN, NO2, C1 to C6 alkyl, substituted C1 to C6 alkyl, alkynyl, or substituted alkynyl, C1 to C6 alkoxy, substituted C1 to C6 alkoxy, amino, C1 to C6 aminoalkyl, or substituted C1 to C6 aminoalkyl; and R5 is selected from a trisubstituted benzene ring of a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO2 or NR6 and containing one or two independent substituents from the group including H, halogen, CN, NO2, amino, and C1 to C3 alky, C1 to C3 alkoxy, C1 to C3 a
    Type: Grant
    Filed: September 6, 2001
    Date of Patent: May 20, 2003
    Assignees: Wyeth, Ligand Pharmaceuticals, Inc.
    Inventors: Puwen Zhang, Eugene A. Terefenko, Andrew Fensome, Jay E. Wrobel, Horace Fletcher, III, Lin Zhi, Todd K. Jones, James P. Edwards, Christopher M. Tegley
  • Publication number: 20030092753
    Abstract: Adatanserin is useful for treating neurodegenerative disorders, chronic pain, and other disorders associated with dysfunctional glutamate release. Methods of treating the same comprise administering a therapeutically effective amount of adatanserin or a pharmaceutical salt thereof, to a patient in need of said treatment.
    Type: Application
    Filed: August 26, 2002
    Publication date: May 15, 2003
    Applicant: Wyeth
    Inventors: Magid A. Abou-Gharbia, James E. Barrett, Wayne E. Childers, John A. Moyer